Gilead Sciences NEWS
Calamos Advisors LLC Raises Stake in Gilead Sciences Inc. (GILD)
- BBNSGilead Sciences
logo Calamos Advisors LLC raised its stake in Gilead Sciences
Inc. (NASDAQ:GILD) by 32.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 723,334 shares ...
Allergan Challenges Intercept With Tobira NASH Drug
- Investor's Business Daily
Allergan (AGN) is taking on Gilead Sciences
(GILD) and Intercept Pharmaceuticals (ICPT) with its acquisition of Tobira Therapeutics (TBRA), but Mizuho analyst Irina Koffler likes the deal, saying a key Tobira drug has "a solid chance of approval ...
Turning Bullish On Gilead - Bezek's Daily Briefing
- Seeking Alpha
With the stock at $120, just a couple bucks short of its all-time high, I called "sell" on Gilead
in a contest-winning article that generated more than 300 comments, mostly negative. That's no surprise, in it, I specifically warned that many people ...
Pro ad report: All the data on journal spending in 1H 2016
- Medical Marketing and Media
Professional advertising spending behind brands like Gilead Sciences
' hepatitis-C pill Harvoni and Allergan's IBS drug Viberzi buoyed med-surg outlays for the first six months of 2016. But cancer drugs once again were the hottest category. Check out ...
Gilead Sciences Videos
Gilead Sciences - Hot or Not
What's Gilead Sciences Doing With All That Cash?
Gilead Sciences Outlook For 2016: What You Need To Know
Fireside Chat With John F. Milligan, PhD, President and Chief Operating Officer, Gilead Sciences
The Next Big Thing In Biotech: Gilead Sciences
What's Behind Gilead Sciences Drop In Hepatitis C Sales?
Gilead Sciences Doesn’t Have Many Fans on Wall Street: Jim Cramer
Dr. Michael Riordan Gilead Sciences founder, CEO Chairman interview 1994
Gilead Sciences: A Bargain Worth Stuffing in Investor Stockings
Gilead Sciences WebSites
Gilead Sciences, Inc. is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines.
Gilead Sciences is an American biopharmaceutical company that discovers, develops and commercializes therapeutics. For many years since the company was founded, the ...
View the basic GILD stock chart on Yahoo Finance. Change the date range, chart type and compare Gilead Sciences, Inc. against other companies.
Gilead Sciences Inc. Stock - GILD news, historical stock charts, analyst ratings, financials, and today’s Gilead Sciences Inc. stock price.
As part of a rapidly growing science-driven organization, colleagues at Gilead are revolutionizing healthcare by bringing urgently needed medicines to patients in the ...
News about Gilead Sciences, Inc. Commentary and archival information about Gilead Sciences, Inc. from The New York Times.
Gilead Sciences, Inc. is actively advancing pharmaceuticals to address unmet medical needs for patients living with life-threatening diseases globally.
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes therapeutics to advance the care of patients ...
Gilead Sciences, Inc. is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of ...
Gilead Sciences Inc, GILD real time stock quotes, news, videos at CNBC.com
Gilead Sciences Wiki
Gilead Sciences is an American biopharmaceutical company that discovers, develops and commercializes therapeutics. For many years since the company was founded, the company concentrated primarily on antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza. In 2006, Gilead acquired two companies which were developing drugs to treat patients with pulmonary diseases.The company's current commercially available products include Atripla, Complera, Emtriva, Viread, Tybost, Vitekta, Truvada, Stribild, Harvoni, Hepsera, Sovaldi, Zydelig, Letairis, Lexiscan, Ranexa, Cayston, Tamiflu, AmBisome, and Macugen.Headquartered and founded in Foster City, California, Gilead has operations in North America, Europe and Australia. As of the end of 2015, the company had approximately 7,900 full-time employees. Gilead is a member of the NASDAQ Biotechnology Index and the S&P 500.The company's name and logo refer to the Balm of Gilead, inspired by a 1965 play by Lanford Wilson featuring the underworld adventures of the patrons of the namesake cafe.